Transplacental passage of nirmatrelvir in pregnant women with COVID-19

Int J Gynaecol Obstet. 2024 Jan;164(1):351-353. doi: 10.1002/ijgo.15147. Epub 2023 Sep 23.

Authors

Ming-Ta Chuang¹, Mei-Tsz Su¹, Chen-Hsi Chou², Yu-Ling Liang¹, Hsing-Fen Tsai¹, Pei-Hsiu Yu¹, Meng-Hsing Wu¹, Wen-Chien Ko³, Pei-Yin Tsai¹

Affiliations

¹ Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
² Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
³ Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

PMID: 37740691
DOI: 10.1002/ijgo.15147

No abstract available

Keywords: COVID-19; Paxlovid; nirmatrelvir; pregnancy; transplacental exposure.

MeSH terms

Antiviral Agents
COVID-19*
Female
Humans
Lactams
Nitriles
Pregnancy
Pregnant Women*

Substances

Lactams
Nitriles
Antiviral Agents

Grants and funding

NCKUH-11109022/National Cheng Kung University Hospital